KLOW is the Glow blend (GHK-Cu, BPC-157 and TB-500) plus KPV, an anti-inflammatory tripeptide cut from alpha-MSH. Each ingredient has animal or lab data, and GHK-Cu has some human skin data, but no trial has tested KLOW. Its four-way “healing” claim is an extrapolation, and none of the four is an FDA-approved drug.[1][4][7]
KLOW has quickly become one of the most searched peptide names, and the explanations that rank for it are mostly vendor pages and forum threads. This page does what those do not. It separates the four ingredients, shows which claims rest on people and which on mice or cell cultures, and states the FDA status of each exactly as FDA.gov listed it on October 2, 2026. Because the three shared ingredients are covered in depth in our Glow peptide blend review, the focus here is on what KPV adds.
What is in KLOW, and how is it different from Glow?
KLOW adds one peptide to Glow. Live Vital, one provider we review, describes its KLOW as a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500. It says the blend can be given by injection, applied topically, or both, with the route and dose set by its physician after intake. The pitch is that the four cover different ground: GHK-Cu for collagen, BPC-157 and TB-500 for tissue repair, and KPV for calming inflammation. That is a reasonable-sounding design. It is not a tested one.
| Glow | KLOW | |
|---|---|---|
| GHK-Cu | Yes | Yes |
| BPC-157 | Yes | Yes |
| TB-500 | Yes | Yes |
| KPV | No | Yes |
| Ingredients with any controlled human trial | 1 (GHK-Cu, mostly topical) | 1 (GHK-Cu, mostly topical) |
| Trials of the blend | None | None |
What does KPV add?
KPV is a tripeptide (lysine, proline, valine) that matches the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH has well-documented anti-inflammatory effects, and researchers have studied short fragments of it as possible anti-inflammatory drugs.[3]
The key KPV studies are in cells and mice. In a 2008 Gastroenterology paper, nanomolar KPV blocked NF-kappaB and MAP kinase inflammatory signaling in human intestinal and immune cell lines. The peptide entered cells through PepT1, a transporter found in the gut. KPV given in drinking water also reduced chemically induced colitis in mice.[1] A second 2008 study found KPV sped recovery in two mouse colitis models. The effect was at least partly independent of the melanocortin-1 receptor, which matters because that receptor drives pigmentation.[2]
Two things follow. First, KPV's evidence is about gut inflammation, with oral dosing in mice. The skin and whole-body claims made for KLOW go beyond what those studies measured. Second, there is no published human trial. The FDA's safety notes say it has not identified any human exposure data for drug products containing KPV.[7] Our KPV evidence review covers the full record, and BPC-157 vs KPV compares the two most-used repair peptides.
Which KLOW claims rest on human data and which on animal data?
| Claim sellers make | Ingredient credited | Where the evidence comes from |
|---|---|---|
| Firmer skin, fewer fine lines | GHK-Cu | Small human studies of topical creams; no injection trial |
| Collagen and tissue remodeling | GHK-Cu | Cell and animal studies; gene-expression analyses |
| Tissue and tendon repair | BPC-157 | Animal studies; one 12-patient uncontrolled knee chart review |
| Cell migration and wound repair | TB-500 | Trials of full-length thymosin beta-4 as eye drops and gels; none of the TB-500 fragment |
| Calmer inflammation | KPV | Cell studies and mouse colitis models; no human trial |
| All of the above, together | The blend | No study of any kind |
The weakest link is the combination itself. A 2025 systematic review of BPC-157 found 35 preclinical studies and 1 clinical study, and no clinical safety data.[5] The human trials of thymosin beta-4 used the full 43-amino-acid protein, not the short TB-500 fragment that sellers use.[6][7] GHK-Cu's controlled human work is topical.[4] Combining four compounds does not add their evidence together. It adds unknowns, including stability in a shared vial, interactions, and how side effects would be traced to one ingredient.
What dose do sellers use?
We do not publish a KLOW dose, because none has been validated. A validated dose comes from trials that compare amounts in people. No such trial exists for KLOW or for any of its four ingredients by injection. Dosing charts online come from vendors and clinicians' own protocols, and KPV in particular has no human dosing data to draw on.[7] Live Vital does not print a fixed dose. It says its physician personalizes the dose, schedule and route after intake. Our KPV dosage explainer sets out why no established human dose exists for that ingredient.
What side effects should you watch for?
Live Vital lists injection-site redness or irritation, mild skin irritation with topical use, rare temporary skin discoloration, rare stomach upset (which it links to oral KPV), nausea, headache and fatigue. It asks people to talk to a clinician first if they have active cancer or a history of it, are pregnant or breastfeeding, have copper sensitivity or Wilson disease, are sensitive to alpha-MSH-derived peptides, take immunosuppressants or anticoagulants, or have liver or kidney disease.
Beyond that list, the FDA flags an immunogenicity risk (unwanted immune reactions) for compounded injectable GHK-Cu and for BPC-157 by certain routes.[7] BPC-157 promotes blood vessel growth in animal studies, which is a theoretical concern for anyone with a tumor.[5] For KPV, the honest answer is that human side effects are unknown because they have not been studied. See KPV side effects for what the animal work shows.
Can a U.S. telehealth provider legally prescribe KLOW?
A licensed clinician can write a prescription. The harder question is whether a pharmacy can lawfully compound it. Under section 503A, a pharmacy may generally compound from a bulk substance only if it is part of an approved drug, has a USP monograph, or is on the FDA's bulks list. None of KLOW's four ingredients meets that test. As FDA.gov listed them on October 2, 2026:
| Ingredient | FDA-approved drug? | 503A compounding status on FDA.gov |
|---|---|---|
| GHK-Cu (injectable) | No | Nominated but withdrawn (April 2026). FDA flags an immunogenicity risk. |
| GHK-Cu (non-injectable) | No | Category 1, under evaluation (restored May 2026) |
| BPC-157 | No | Nominated but withdrawn (April 2026). Advisory committee recommended it for the bulks list in July 2026; FDA has not acted. |
| TB-500 | No | Nominated but withdrawn (April 2026). Same July 2026 recommendation; FDA has not acted. |
| KPV | No | Nominated but withdrawn (April 2026). FDA found no human exposure data. Same July 2026 recommendation; FDA has not acted. |
“Nominated but withdrawn” means these substances left Category 2 in April 2026 because their nominations were withdrawn. It does not mean they were cleared for compounding.[7] In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, TB-500 and KPV for the bulks list. The FDA has not acted on those votes, and they are not binding.[9][10] Only the non-injectable form of GHK-Cu is back in Category 1.[8] Our peptide legality guide follows each change.
What should you ask a provider before starting KLOW?
Because KLOW has no standard formula, the useful questions are about the specific vial you would receive. Ask for the milligrams of each of the four peptides per vial, not just the total. Ask which pharmacy compounds it and whether that pharmacy operates under section 503A or 503B. Ask whether you can see a certificate of analysis for the batch, showing identity, purity and sterility testing. Ask how long the mixed vial stays usable and how it should be stored. And ask who you contact if you have a reaction. A provider that cannot answer these is asking you to trust a label that nobody has checked.
What does KLOW cost through providers we have reviewed?
Live Vital lists KLOW on its public site (read October 2, 2026) at $449 for a 10-week protocol, presented as $149 a month. Over 30 days that comes to about $192, the same as its Glow. Live Vital is a commercial partner of Aminoscope. Our Live Vital review covers how it prices and who prescribes. Other peptide providers are on our peptide therapy provider list, where partners appear first. For the anti-inflammatory alternatives sellers often mention alongside KPV, see KPV vs LL-37.
The bottom line
KLOW takes Glow's thin evidence base and adds a fourth ingredient with no human data at all. Each component has a plausible mechanism, and KPV's anti-inflammatory signal in mice is genuine. But “calm, rebuild, repair and restore” describes a hope, not a result anyone has measured. If you consider it, use a prescription from a clinician who knows your history and a named US pharmacy, and expect the regulatory picture to keep changing.
